Spots Global Cancer Trial Database for Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Official Title: A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Study ID: NCT00435916
Interventions
Study Description
Brief Summary: This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic-Arizona, Scottsdale, Arizona, United States
University of California Los Angeles, Los Angeles, California, United States
Stanford University Medical Center, Palo Alto, California, United States
Sharp Healthcare, San Diego, California, United States
Georgetown University, Washington, District of Columbia, United States
Northwestern University, Chicago, Illinois, United States
Rush University Medical Center, Chicago, Illinois, United States
Mayo Clinic-Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, St. Louis, Missouri, United States
Weill Medical College of Cornell University, New York, New York, United States
Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States
Swedish Cancer Institute, Seattle, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Contact Details
Name: Nancy Whiting, PharmD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
